Acute dystonic reaction to methotrimeprazine in hypoparathyroidism

Annals of Pharmacotherapy

Volumn 30, Issue 9, 1996, Pages 957-959

  Gur, Hanan ^a,b   Paz, Yoav ^a,b   Sidi, Yechezkel ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CALCIUM; CALMODULIN; LEVOMEPROMAZINE; PHENOTHIAZINE;

AGED; ARTICLE; CALCIUM BLOOD LEVEL; CASE REPORT; DISORIENTATION; DOSE RESPONSE; DRUG MECHANISM; DYSTONIA; ENZYME ACTIVATION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOCALCEMIA; HYPOPARATHYROIDISM; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029813717     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000908     Document Type: Article

References (18)

1. Snyder SH. Drug and neurotransmitter receptors: new perspectives with clinical relevance. JAMA 1989;261:3126-9.
2. O'Hara VS. Extrapyramidal reactions in patients receiving prochlorperazine. N Engl J Med 1958;259:826-8.
3. Dystonia: underdiagnosed and undertreated? Drug Ther Bull 1988;26: 33-6.
4. Schaaf M, Payne CA. Dystonic reactions to prochlorperazine in hypoparathyroidism. N Engl J Med 1966;275:991-5.
5. Schnell RG. Drug-induced dyskinesia treated with intravenous diazepam. J Fla Med Assoc 1972;59:22-3.
6. Potts JT Jr. Diseases of the parathyroid gland and other hyper- and hypocalcemic disorders. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's principles of internal medicine, International Edition. 13th ed. New York: McGraw-Hill, 1994:2151-71.
7. Foley J. Calcification of corpus striatum and dentate nuclei occurring in a family. J Neurol Neurosurg Psychiatry 1951;14:253-61.
8. Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 1977;196: 326-8.
9. Maher P, Singer SJ. Structural changes in membranes produced by the binding of small amphipathic molecules. Biochemistry 1984;23:232-40.
10. Salzman C, Shader RI, Pearlman M. Psychopharmacology and the elderly. In: Shader RI, DiMascio A, eds. Psychotropic drug side effects. Baltimore: Williams and Wilkins, 1970:261-79.
11. Babu YS, Sack JS, Greenhogh TJ, Bugg CE, Means AR, Cook WJ. Three-dimensional structure of calmodulin. Nature 1985;315:37-40.
12. Levin RM, Weiss B. Selective binding of antipsychotics and other psychoactive agents to the calcium-dependent activator of cyclic nucleotide phosphodiesterase. J Pharmacol Exp Ther 1979;2083:454-98.
13. Ahlijianian MK, Cooper DMF. Calmodulin may play a pivotal role in neurotransmitter-mediated inhibition and stimulation of rat cerebellar adenylate cyclase. Mol Pharmacol 1987;32:127-32.
14. Cheung WY. Calmodulin plays a pivotal role in cellular regulation. Science 1980;207:19-27.
15. Ahlijianian MK, Cooper DMF. Antagonism of calmodulin-stimulated adenylate cyclase by trifluoperazine, clamidazolium and W-7 in rat cerebellar membranes. J Pharmacol 1987;241:407-14.
16. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsycholic drugs doses and neuroleptic/dopamine receptors. Nature 1976;261:717-9.
17. Weiss B, Greenberg LH. Modulation of beta-adrenergic receptors and calmodulin following acute and chronic treatment with neuroleptics. In: Cattabenu F, Racagni G, Spano PF, Costa E, eds. Long term effects of neuroleptics. Advances in Biochemistry and Psychopharmacology. Vol 24. New York: Raven Press, 1980:139-46.
18. Lejoyeux M, Maziere JC. Could the interaction of neuroleptics with calmodulin be an "explanation" of the psychotropic effects? Encephale 1991;17:11-5.